scholarly journals Identification of a Four-miRNA Signature Predicts Prognosis in Papillary Thyroid Cancer

2021 ◽  
Author(s):  
YANG FAN ◽  
Hongzhong zhou
Keyword(s):  
Thyroid Cancer ◽  
High Risk ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid ◽  
Normal Tissues ◽  
Significant Difference ◽  
Differentially Expressed Mirnas ◽  
Score Model ◽  
New Biomarkers

Abstract Background: In newly diagnosed patients with thyroid cancer, papillary thyroid cancer (PTC), accounts for ninety percent of all cases. Although PTC is known as a relatively adolescent malignant disease, there still is a high possibility of recurrence in PTC patients, who suffered from poor prognosis. Therefore, new biomarkers are necessary to guide more effective stratification of PTC patients and personalization of therapy to avoid overtreatment or inadequate treatment. Accumulating evidence demonstrates that miRNAs have broad application prospects as diagnostic biomarkers in cancer. Methods: The present study aims to explore novel markers consists of miRNA-associated signature for PTC prognostication, utilizing data from the TCGA database. We obtained and analyzed data of 497 PTC patients from the TCGA. The patients were randomly assigned to a training cohort or testing cohort. Results: We discovered 237 differentially expressed miRNAs in tumorous thyroid tissues comparing to normal tissues The effect evaluation of excavated differently expressed miRNAs was conducted by our risk score model. We then successfully generated a four-miRNA potential prognostic signature, which reliably distinguishes patients from high risk and low risk with a significant difference in overall survival (P <0.01) and was effective in predicting five-year disease survival. Conclusions: Our results indicated a four miRNAs signature that has a robust predicting effect on the prognosis of PTC. Therefore, we would recommend more radical treatment and closer follow-up of high-risk individuals.

scholarly journals Relationship between focality and cervical lymph nodes metastasis in papillary thyroid carcinoma

2019 ◽  
Vol 6 (2) ◽  
pp. 453
Author(s):  
Tarek M. Rageh ◽  
Rehab M. Samaka ◽  
Mahmoud G. Hagag ◽  
Elsayed A. Motawa
Keyword(s):  
Thyroid Cancer ◽  
High Risk ◽  
Lymph Nodes ◽  
Papillary Thyroid Cancer ◽  
High Rate ◽  
Capsular Invasion ◽  
Papillary Thyroid ◽  
Cervical Lymph Nodes ◽  
Cancer Management

Background: Papillary Thyroid Cancer (PTC) is the most common malignancy in thyroid gland and may be unifocal or multifocal. This study compares between unifocal and multifocal PTC to clarify which type has an aggressive behaviour.Methods: This retrospective and prospective cross-sectional study was done on one hundred PTC patients who underwent papillary thyroid cancer management. The unifocal and multifocal groups each one contains 50 patients. The study was done in the period between January 2015 to January 2018. Other types of cancer thyroid and distant metastatic thyroid cancer were excluded from the study. All patients underwent follow up for one year.Results: There are significant differences between unifocal and multifocal PTC regarding to age, the number of positive lymph nodes, history of multinodular goiter (MNG) and capsular invasion. The capsular invasion in multifocal increase the recurrence rate (P=0.03).Conclusions: The new proposed method for PTC tumor size assessment could be a valuable in multifocal PTC patient’s stratification into low risk and high-risk subgroups. Therefore, high risk multifocal PTC patients could have a poor prognosis and high rate of recurrence, for that require aggressive treatment and strict follow up.

Abstract 730: Annual hazard rate of recurrence in Middle-Eastern papillary thyroid cancer over a long-term follow-up

2021 ◽  
Author(s):  
Abdul K. Siraj ◽  
Sandeep K. Parvathareddy ◽  
Zeeshan Qadri ◽  
Saud Azam ◽  
Felisa De Vera ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Hazard Rate ◽  
Middle Eastern ◽  
Papillary Thyroid ◽  
Long Term Follow Up

scholarly journals MON-LB82 Plasma Expression Level of MiRNA -21 Is Related With the Presence of Papillary Thyroid Cancer

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Birute Zilaitiene ◽  
Aiste Kondrotiene ◽  
Daina Pamedytyte ◽  
Vaida Simanaviciene ◽  
Dalia Dauksiene ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Healthy Volunteers ◽  
Papillary Thyroid Cancer ◽  
Diagnostic Value ◽  
Healthy Controls ◽  
Papillary Thyroid ◽  
Expression Levels ◽  
Significant Difference ◽  
Baseline Levels ◽  
Benign Nodules

Abstract Introduction.: There is no effective and reliable biomarker to distinguish benign thyroid nodules (BTN) from papillary thyroid carcinomas (PTC). In this study we analyzed a set of four miRNA molecules in plasma of patients with papillary thyroid cancer, benign nodules and healthy controls to identify miRNA molecules that may be markers of PTC.Aim.: We aimed to investigate the dysregulation of plasma miRNAs in PTC and evaluate the diagnostic value for differentiation of PTC from BTN. Methods.: The expression levels of 4 miRNAs (miR-221, miR-222, miR-146b, miR-21) were measured in 48 PTC patients before thyroidectomy and again after thyroidectomy in a subgroup of 36 patients. Preoperative and postoperative plasma miRNA expression levels were compared with baseline levels established in plasma from the heathy controls group (N=57) and patients with BTN (N=22). MicroRNA-222 and miR-146b, miR-221, miR-21 were included in a panel because they all reportedly were overexpressed in PTC compared to benign nodules or normal thyroid tissue.Results.: Compared with baseline levels in the healthy controls group, miR-221, miR-222, miR-146b, miR-21 levels were significantly higher in the preoperative PTC group (P &lt;0.0001, P=0.002, P=0.028, P =0.021, respectively). A significant reduction in miR-21 expression was observed in postoperative PTC patients. MiR-21 decreased by 5.98-fold (P=0.046) in post- operative samples compared with preoperative samples in the PTC patients.In comparison MiRNRs expression levels in BTN group with healthy controls, miR-221, miR-21 expression levels were significantly higher in the BTN group (P=0.003, P=0.048, respectively). No significant difference was observed between the preoperative PTC group and the preoperative BTN group with regard to the expression of these four miRNA’s. Conclusions: The expression levels of miR-222, miR-146b in plasma were significantly higher in patients who had PTC than in healthy volunteers, whereas levels of miR-221, miR-21 in plasma were significantly higher in patients who had either PTC or BTN before thyroidectomy than in healthy volunteers. Furthermore, miR-21 showed a significant reduction of expression levels after thyroidectomy in PTC patients. However, value of these four miRNAs is still limited in differential diagnosis of PTC and benign nodules.

scholarly journals MON-533 Diffuse Sclerosing Variant Papillary Thyroid Cancer: Clinical and Histopathological Features, Mutational Profile, Management and Outcome

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Abeer Abdulhadi Aljomaiah ◽  
Yosra Moria ◽  
Nora Aldaej ◽  
Meshael Alswailem ◽  
Ali Saeed Alzahrani
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Molecular Genetics ◽  
Papillary Thyroid Cancer ◽  
Distant Metastases ◽  
The Other ◽  
Papillary Thyroid ◽  
Histopathological Features ◽  
Diffuse Sclerosing Variant

Abstract Diffuse sclerosing variant (DSV) is a rare subtype of papillary thyroid cancer (PTC). Whether it represents a higher grade subtype than conventional PTC is not quite clear. Furthermore, there are limited data on its long-term outcome and its molecular genetics. In this report, we studied all cases of DSV PTC seen at our center during the last 20 years. Out of more than 6000 patients (pts) with differentiated thyroid cancer, only 37 were DSV. We reviewed the clinical and histopathological features, management and outcome of these cases. In addition, molecular genetics is partially achieved; 17 out of these 37 cases have been genotyped for BRAFV600E, TERT promotor mutations, NRAS, HRAS and KRAS mutations. The molecular profiling of the other 20 cases is being done. A total of 37 pts were studied {(12 Males:25 Females, median age 21 years (8-89)}. One pt had lobectomy and the other 36 pts (97.3%) had a total thyroidectomy. Central only (4 pts) or central/lateral lymph node dissection (29 pts) were performed. The median tumor size was 4.5 cm (1.5-8.1). The tumor was multifocal in 27 cases (73%), with extrathyroidal invasion in 27 (73%) and lymphovascular invasion in 24 pts (64.8%). A background lymphocytic thyroiditis was present in 12 pts (32.4%). Lymph node metastases were present in 34 pts (92%) and distant metastases in 13 pts (35%). The sites of metastasis are lungs in 12 pts (32.4%) and lungs and bone in 1 pt. Twenty pts (54.1%) were in TNM8 stage 1, 10 pts (27%) in stage 2, 1 (2.7%) in stage 4a, 3 (8.1%) in stage 4b and 3 unstageable. The ATA risk classification for these pts was 4 pts (10.8%) in low, 12 (32.4%) in intermediate, 19 (51.4%) in high-risk groups and 2 could not be assessed. I-131 was administered to 33 pts (89.2%). The median administered activity was 136 mCi (46-218). Fifteen pts (40.5%) received additional therapies (3 surgeries, 7 RAI, 5 surgeries, and RAI). In 17 pts (46%) which were genotyped, only 3 tumors (8.1%) had BRAFV600E mutation, 1 (2.7%) had TERT promotor C228T mutation and none had RAS mutations. At the last follow up, 15 pts (40.5%) achieved an excellent response, 9 (24%) an indeterminate response, 6 (16.2%) with a structural disease, and 7 (19%) were lost for follow up. Conclusion: DSV PTC is a rare variant, occurs mostly in adolescent and young pts, characterized by aggressive histopathological features and high rates of lymph node and distant metastases but the commonly reported mutations in PTC are rare in DSV and mortality is absent.

scholarly journals Splenectomy for Solitary Splenic Metastasis in Recurrent Papillary Thyroid Cancer. A Case Report and Literature Review

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Antonio Maffuz-Aziz ◽  
Gabriel Garnica ◽  
Silvia López-Hernández ◽  
Janet Pineda-Diaz ◽  
Javier Baquera-Heredia ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Lung Metastases ◽  
The United States ◽  
Central Neck Dissection ◽  
Splenic Metastasis ◽  
Papillary Thyroid ◽  
Rare Manifestation ◽  
Tall Cell

Thyroid cancer is the most common endocrine malignancy, presenting with 23 500 new cases per year in the United States. About 7-23% of the patients will present recurrent metastases disease during follow-up. The classic variant of papillary carcinoma is less aggressive compared to its other variants like diffuse sclerosing, tall cell or columnar cell, and insular variants, and the sites to which this metastasizes is already well identified. Metastasis to the spleen is an extremely rare manifestation of papillary thyroid cancer. To date, only 3 cases have been reported in the literature. Herein, we present a 52-year-old male, who developed spleen metastases, 2.4 years after total thyroidectomy and central neck dissection followed by radioactive iodine ablation and seven months after treatment with sorafenib for lung metastases. The splenic lesion was detected in surveillance studies. This case highlights that splenic metastasis, although rare, may occur even in a patient with a locoregional and systemic controlled thyroid cancer and that it can be treated safely with surgical resection.

Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study

2016 ◽  
Vol 85 (3) ◽  
pp. 466-474 ◽  
Author(s):  
Taciana Padilha de Castro ◽  
William Waissmann ◽  
Taynãna César Simões ◽  
Rossana Corbo R. de Mello ◽  
Denise P. Carvalho
Keyword(s):  
Cohort Study ◽  
Thyroid Cancer ◽  
Retrospective Analysis ◽  
Papillary Thyroid Cancer ◽  
Papillary Thyroid

scholarly journals Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy

2009 ◽  
Vol 94 (5) ◽  
pp. 1618-1622 ◽  
Author(s):  
Paolo Miccoli ◽  
Aldo Pinchera ◽  
Gabriele Materazzi ◽  
Agnese Biagini ◽  
Piero Berti ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Minimally Invasive ◽  
Papillary Thyroid Cancer ◽  
Intermediate Risk ◽  
Papillary Thyroid ◽  
Conventional Thyroidectomy ◽  
Video Assisted ◽  
Group A ◽  
Group B

Abstract Background: Minimally invasive video-assisted thyroidectomy (MIVAT) was introduced in the clinical practice to treat small benign thyroid nodules. This method has recently been demonstrated to produce the same completeness as a conventional thyroidectomy in patients with papillary thyroid cancer (PTC). The low number of treated cases and the limited follow-up of these patients represent the major limitations of these studies. Objective: The aim of the study was to compare the outcome of two groups of PTC patients, one treated with MIVAT and the other with conventional thyroidectomy, after a median follow-up of 5 yr. Study Group: A total of 221 PTC patients were enrolled in this study according to the following criteria: 171 were treated with MIVAT (group A), and 50 were treated with conventional thyroidectomy (group B). Results: The outcome and the cumulative 131I activity administered to achieve curative status were compared. After a mean follow-up of 3.6 ± 1.5 yr (range, 1–8 yr; median, 5 yr), no differences were found between group A and group B. A similar rate of permanent hypoparathyroidism and/or nerve cord palsy was found in both groups. Conclusion: We demonstrated that PTC patients operated on with MIVAT had a good outcome after 5 yr. This was similar to the outcome of patients treated with conventional thyroidectomy and the same degree of exposure to 131I. These results, together with the evidence of a similar degree of completeness and rate of complications between the two surgical techniques, show that MIVAT is a valid option to treat low- and intermediate-risk PTC patients.

Sign in / Sign up

Export Citation Format

Share Document